The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a …
RNA Black, CN Ennis, IS Young, SJ Hunter… - Journal of Diabetes and …, 2014 - Elsevier
Aims Assess insulin sensitivity after treatment with a selective PPAR-alpha agonist
compared to an HMG CoA reductase inhibitor in human subjects with type 2 diabetes
mellitus. Methods Thirteen subjects with Type 2 diabetes mellitus were studied in a double-
blind crossover design with 4-week placebo run-in and washout and 12-week treatment
periods, randomised to micronised fenofibrate 267 mg or atorvastatin 10 mg daily followed
by the alternate drug in the second period. Insulin resistance was measured using the …
compared to an HMG CoA reductase inhibitor in human subjects with type 2 diabetes
mellitus. Methods Thirteen subjects with Type 2 diabetes mellitus were studied in a double-
blind crossover design with 4-week placebo run-in and washout and 12-week treatment
periods, randomised to micronised fenofibrate 267 mg or atorvastatin 10 mg daily followed
by the alternate drug in the second period. Insulin resistance was measured using the …